Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist

David G. Johnson, Camy Ulichny Goebel, Victor J. Hruby, Marvin D. Bregman, Dev Trivedi

Research output: Contribution to journalArticle

131 Scopus citations

Abstract

The glucagon analog [l-Nα-trinitrophenylhistidine, 12-homoarginine]glucagon (THG) was examined for its ability to lower blood glucose concentrations in rats made diabetic with streptozotocin. In vitro, THG is a potent antagonist of glucagon activation of the hepatic adenylate cyclase assay system. Intravenous bolus injections of THG caused rapid decreases (20 to 35 percent) of short duration in blood glucose. Continuous infusion of low concentrations of the inhibitor led to larger sustained decreases in blood glucose (30 to 65 percent). These studies demonstrate that a glucagon receptor antagonist can substantially reduce blood glucose levels in diabetic animals without addition of exogenous insulin.

Original languageEnglish (US)
Pages (from-to)1115-1116
Number of pages2
JournalScience
Volume215
Issue number4536
DOIs
StatePublished - Jan 1 1982

    Fingerprint

ASJC Scopus subject areas

  • General

Cite this